

Disclosure of Transfers of Value Methodology Note for Tetriz Pharma 2021

Tetriz Pharma methodology, 2021

Tetriz Pharma began trading in July 2021 and is a specialty pharmaceutical business focused on taking branded medicines to market as well as developing and acquiring niche injectable and topical products. During 2021 one branded and five generic products were marketed by Tetriz Pharma solely in the UK. Non- research and development activity was limited to a single UK advisory board. No research and educational grants and donations were made. Tetriz Pharma had no active product development programmes in 2021. All payments during the chronological year 2021 were reviewed. The total spend was reviewed with finance functions. The aggregated total is declared on the accompanying spread sheet.

In collating disclosure data, the following methodologies have been used:

- Amounts declared included VAT applied
- Amounts declared are in UK sterling.
- There were no other payments worldwide.
- Contracts were for a single year of 2021
- Tetriz Pharma does not have any over the counter business or medical device business.
- Individual consent has been sought for individual payments to healthcare professionals with no refusals
- Tetriz Pharma has made no non-monetary transfers of value in 2021
- Tetriz Pharma has no joint working to disclose in 2021
- Tetriz Pharma made no Unrestricted educational grants to patient groups or Donations to patient groups in 2021